Researchers Announce Results of New COVID sa-mRNA Vaccine
Pharmacy Times reported: New study findings announced updated results from a follow-up analysis of a phase 3 study that evaluated the ARCT-154 booster dose. Researchers reported that ARCT-154 displayed a longer immune response 6 months prior to vaccination to prevent infection of the Wuhanstrain and Omicron BA.4/5. The study authors noted that ARCT-154 is the first approved self-amplifying messenger RNA(sa-mRNA) COVID-19 immunization. The…